
BIOS Health is at the forefront of a new era in precision medicine by leveraging AI to analyze the nervous system. The company builds infrastructure for the discovery, development, and delivery of future neural treatments. Their proprietary neural interface and AI platform can read and write the body's neural data in real-time to understand and correct faulty signals that cause disease. BIOS envisions neural digital therapies that utilize this data for better, more targeted pharmaceuticals and software-delivered treatments. They offer partnerships for co-development and their technology can provide real-time insights into pharmaceutical effects on the nervous system, reducing feedback time from months to minutes.

BIOS Health is at the forefront of a new era in precision medicine by leveraging AI to analyze the nervous system. The company builds infrastructure for the discovery, development, and delivery of future neural treatments. Their proprietary neural interface and AI platform can read and write the body's neural data in real-time to understand and correct faulty signals that cause disease. BIOS envisions neural digital therapies that utilize this data for better, more targeted pharmaceuticals and software-delivered treatments. They offer partnerships for co-development and their technology can provide real-time insights into pharmaceutical effects on the nervous system, reducing feedback time from months to minutes.
What they do: AI-driven neural interfaces and neural biomarkers to read/write nervous-system signals for precision therapies
Founded: 2015
Founders: Emil Hewage; Oliver Armitage
Headcount (approx.): 26
Total disclosed funding: USD 46,796,540
Neurotechnology / precision medicine for disorders rooted in faulty nervous-system signaling
2015
Biotechnology
USD 4,500,000
Seed round announced to expand technical team and develop neural-interface technology.
“Has raised institutional venture funding from investors including Real Ventures, AME Cloud Ventures, Selvedge Venture, XTX Ventures, Fifty Years and participation in Y Combinator”